Thus, we hypothesized that the combination of small molecule inhibitors targeting ATM with TOP2-targeting medications may not only synergistically suppresses lung cancer cell survival but also attenuate the DNA damage response, thus lowering the possibility of cardiotoxicity and secondary malignancy caused by therapy. Here, ATM is linked to lung cancer.